Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Pediatric STEC-HUS
NCT02205541Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in hemolytic uremic syndrome (HUS) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Duration of extrarenal epuration at 13 months. Started Jun 2015; status: completed.
02
Drugs
eculizumab
03
Conditions
hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on NCT02205541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205541.